The undeniable TRUTH about statins: Cholesterol lowering

New Post Public Reply Private Reply Replies (1) Message Board
wowhappens28
256
The undeniable TRUTH about statins: Cholesterol lowering drugs are linked to memory loss and brain impairment

https://www.naturalhealth365.com/statins-drug...-2798.html

If you have high cholesterol, your conventionally-trained physician has probably told you about the ‘value’ of statins to lower your cholesterol.

The problem is: these cholesterol lowering drugs have serious side effects – including memory issues and other brain-related problems. Today, we feature the latest (shocking) news about these drugs. But, remember, don’t ever stop taking a medication prescribed by your doctor without talking about strategy that works best for you.

To be perfectly clear, pharmaceutical companies don’t really want the public to know this, but cognitive decline and memory loss are major side effects of this controversial (and highly profitable) drug class.

People who take statins are more likely to experience learning difficulties, memory loss and depression
Systematic reviews of the literature have already drummed up dozens of high quality studies showing how statins (called called HMG-CoA reductase inhibitors) cause adverse effects, including neuropathy, sexual dysfunction, liver damage, high blood sugar, and muscle pain (to name a few).

But perhaps one of the most troubling adverse effects is cognitive impairment – specifically memory loss. It’s even listed right on the prescription bottle as a side effect!

Other cognitive-related problems caused by statins include learning difficulties, irritability, depression, and anxiety. Plus, research indicates that almost half of all women taking statins develop diabetes – a life-altering chronic condition that can significantly increase the risk of developing Alzheimer’s disease or other forms of dementia.

Myth EXPOSED: Cholesterol isn’t even the main culprit behind heart disease
High cholesterol has been more or less demonized by the media over the past several decades. But the REAL major culprits behind heart disease have nothing to do with how much cholesterol you have in your blood!

In fact, the real factors that effect heart health include: stress, sugar, trans fat, inflammation and free radicals. Another thing, hard to believe for many people taking statins, is that these drugs can actually cause heart disease.

With all this in mind, you may be wondering (like we are) why so many doctors still recommend statins as the go-to line of defense against cholesterol. Not to be cynical, but here’s a hint: Big pharma is a lot like politics – just follow the money.

Statins are the best-selling prescription drug class in the United States. Atorvastatin (you’ve seen it blasted all over commercials as Lipitor) is the best-selling prescription drug in the world.

We’ll wrap up by pointing out a frank and potentially frightening correlation:

More than 20% of Americans between the ages of 40 and 75 are currently taking statins – and the U.S. CDC readily admits that the prevalence is on the rise.
What’s also on the rise in this country? Dementia, and specifically Alzheimer’s disease – now the sixth leading cause of death in our country.
And while the research can’t definitively say (yet) if statins are a driving cause of this growing problem, we find it hard to pass up as pure coincidence.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 392

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
YSTUDIO's Pens: A Nod to the Power of Writing

Updated Category News Views 404

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 291

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading
HONGQI's EHS4 Launch in Europe: Bridging East and West

Updated Category News Views 127

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 346

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 181

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 103

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
PASCAL's Holiday Gift Edit: Timeless Watches Shine

Updated Category News Views 273

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

Continue Reading
Luvme Hair Offers Wig Variety for Winter Fashion

Updated Category News Views 337

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 28

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading

Top 5 Most Recently Viewed Articles

Prudent Growth Partners Expands with Castle Shops Acquisition

Updated Category News Views 174

Prudent Growth Partners Enhances Retail Portfolio Prudent Growth Partners, LLC, a well-established private equity real estate firm, has recently made a significant leap forward by acquiring Castle Shops for $5.4 million. This 37,309 square foot retail center is situated in a bustling area, presenting exciting opportunities for growth and development. Strategic Location of...

Continue Reading
TOYO Co., Ltd Unveils Ambitious Solar Manufacturing Project

Updated Category News Views 220

TOYO Co., Ltd Unveils Plans for Solar Manufacturing Facility TOYO Co., Ltd (NASDAQ: TOYO), a leading company specializing in solar solutions, is thrilled to reveal its plans for a cutting-edge solar cell manufacturing facility. This new plant is expected to have an impressive annual capacity of 2 gigawatts (GW), reflecting TOYO's commitment to advancing renewable energy...

Continue Reading
Future Trends in the AI Semiconductor Ecosystem Explained

Updated Category News Views 331

Understanding the AI Semiconductor Ecosystem The AI semiconductor ecosystem is evolving rapidly, a movement driven largely by the increasing need for computational power essential for artificial intelligence advancements. This sector has reached a pivotal point where the demand for AI-powered solutions, especially large language models, significantly exceeds current chip...

Continue Reading
Broadwind Set to Release Year-End 2024 Results Soon

Updated Category News Views 199

Broadwind's Upcoming Financial Results Announcement Broadwind (Nasdaq: BWEN), a leading precision manufacturer known for its specialized components and solutions, has exciting news. They are set to announce their financial results for the fourth quarter and full year of 2024. This important update will occur before the market begins on a scheduled day. Conference Call...

Continue Reading
Snowflake Stock Earnings Rollercoaster: The Good and Bad

Updated Category News Views 305

Rocky Road for Snowflake: Earnings Highlights Turn the lights on, folks. Right when you thought Snowflake was ready to soar, the stock pulled some classic market gymnastics. This company just reported a fourth-quarter revenue of $1.28 billion, which isn't just pocket change; that’s $50 million over what the analysts were slinging around, estimating a mere $1.26 billion...

Continue Reading